The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gram-Negative Bacterial Infection Therapeutics Market Research Report 2025
Synopsis
Gram-negative bacteria generally refer to bacteria that show red in the gram-negative staining reaction.
The global Gram-Negative Bacterial Infection Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gram-Negative Bacterial Infection Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gram-Negative Bacterial Infection Therapeutics.
Report Scope
The Gram-Negative Bacterial Infection Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gram-Negative Bacterial Infection Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gram-Negative Bacterial Infection Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Baxter
Sanofi
GlaxoSmithKline
Novartis
Pfizer
Takeda
Nektar Therapeutics
Sumitomo
Targeted Genetics
Segment by Type
Enteral Treatment
Parenteral Treatment
Topical Treatment
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gram-Negative Bacterial Infection Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Gram-negative bacteria generally refer to bacteria that show red in the gram-negative staining reaction.
The global Gram-Negative Bacterial Infection Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gram-Negative Bacterial Infection Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gram-Negative Bacterial Infection Therapeutics.
Report Scope
The Gram-Negative Bacterial Infection Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gram-Negative Bacterial Infection Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gram-Negative Bacterial Infection Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Baxter
Sanofi
GlaxoSmithKline
Novartis
Pfizer
Takeda
Nektar Therapeutics
Sumitomo
Targeted Genetics
Segment by Type
Enteral Treatment
Parenteral Treatment
Topical Treatment
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gram-Negative Bacterial Infection Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Enteral Treatment
1.2.3 Parenteral Treatment
1.2.4 Topical Treatment
1.3 Market by Application
1.3.1 Global Gram-Negative Bacterial Infection Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gram-Negative Bacterial Infection Therapeutics Market Perspective (2019-2030)
2.2 Gram-Negative Bacterial Infection Therapeutics Growth Trends by Region
2.2.1 Global Gram-Negative Bacterial Infection Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Gram-Negative Bacterial Infection Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Gram-Negative Bacterial Infection Therapeutics Market Dynamics
2.3.1 Gram-Negative Bacterial Infection Therapeutics Industry Trends
2.3.2 Gram-Negative Bacterial Infection Therapeutics Market Drivers
2.3.3 Gram-Negative Bacterial Infection Therapeutics Market Challenges
2.3.4 Gram-Negative Bacterial Infection Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gram-Negative Bacterial Infection Therapeutics Players by Revenue
3.1.1 Global Top Gram-Negative Bacterial Infection Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Gram-Negative Bacterial Infection Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gram-Negative Bacterial Infection Therapeutics Revenue
3.4 Global Gram-Negative Bacterial Infection Therapeutics Market Concentration Ratio
3.4.1 Global Gram-Negative Bacterial Infection Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gram-Negative Bacterial Infection Therapeutics Revenue in 2023
3.5 Gram-Negative Bacterial Infection Therapeutics Key Players Head office and Area Served
3.6 Key Players Gram-Negative Bacterial Infection Therapeutics Product Solution and Service
3.7 Date of Enter into Gram-Negative Bacterial Infection Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gram-Negative Bacterial Infection Therapeutics Breakdown Data by Type
4.1 Global Gram-Negative Bacterial Infection Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Type (2025-2030)
5 Gram-Negative Bacterial Infection Therapeutics Breakdown Data by Application
5.1 Global Gram-Negative Bacterial Infection Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Gram-Negative Bacterial Infection Therapeutics Market Size (2019-2030)
6.2 North America Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2019-2024)
6.4 North America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gram-Negative Bacterial Infection Therapeutics Market Size (2019-2030)
7.2 Europe Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2019-2024)
7.4 Europe Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gram-Negative Bacterial Infection Therapeutics Market Size (2019-2030)
9.2 Latin America Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Baxter
11.1.1 Baxter Company Detail
11.1.2 Baxter Business Overview
11.1.3 Baxter Gram-Negative Bacterial Infection Therapeutics Introduction
11.1.4 Baxter Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
11.1.5 Baxter Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Gram-Negative Bacterial Infection Therapeutics Introduction
11.2.4 Sanofi Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
11.2.5 Sanofi Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Detail
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Introduction
11.3.4 GlaxoSmithKline Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
11.3.5 GlaxoSmithKline Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Gram-Negative Bacterial Infection Therapeutics Introduction
11.4.4 Novartis Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Gram-Negative Bacterial Infection Therapeutics Introduction
11.5.4 Pfizer Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Takeda
11.6.1 Takeda Company Detail
11.6.2 Takeda Business Overview
11.6.3 Takeda Gram-Negative Bacterial Infection Therapeutics Introduction
11.6.4 Takeda Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
11.6.5 Takeda Recent Development
11.7 Nektar Therapeutics
11.7.1 Nektar Therapeutics Company Detail
11.7.2 Nektar Therapeutics Business Overview
11.7.3 Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Introduction
11.7.4 Nektar Therapeutics Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
11.7.5 Nektar Therapeutics Recent Development
11.8 Sumitomo
11.8.1 Sumitomo Company Detail
11.8.2 Sumitomo Business Overview
11.8.3 Sumitomo Gram-Negative Bacterial Infection Therapeutics Introduction
11.8.4 Sumitomo Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
11.8.5 Sumitomo Recent Development
11.9 Targeted Genetics
11.9.1 Targeted Genetics Company Detail
11.9.2 Targeted Genetics Business Overview
11.9.3 Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Introduction
11.9.4 Targeted Genetics Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
11.9.5 Targeted Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Enteral Treatment
Table 3. Key Players of Parenteral Treatment
Table 4. Key Players of Topical Treatment
Table 5. Global Gram-Negative Bacterial Infection Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Gram-Negative Bacterial Infection Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Region (2019-2024)
Table 9. Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Region (2025-2030)
Table 11. Gram-Negative Bacterial Infection Therapeutics Market Trends
Table 12. Gram-Negative Bacterial Infection Therapeutics Market Drivers
Table 13. Gram-Negative Bacterial Infection Therapeutics Market Challenges
Table 14. Gram-Negative Bacterial Infection Therapeutics Market Restraints
Table 15. Global Gram-Negative Bacterial Infection Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Players (2019-2024)
Table 17. Global Top Gram-Negative Bacterial Infection Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gram-Negative Bacterial Infection Therapeutics as of 2023)
Table 18. Ranking of Global Top Gram-Negative Bacterial Infection Therapeutics Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Gram-Negative Bacterial Infection Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Gram-Negative Bacterial Infection Therapeutics Product Solution and Service
Table 22. Date of Enter into Gram-Negative Bacterial Infection Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Gram-Negative Bacterial Infection Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Type (2019-2024)
Table 26. Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Type (2025-2030)
Table 28. Global Gram-Negative Bacterial Infection Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Application (2019-2024)
Table 30. Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Application (2025-2030)
Table 32. North America Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 47. Baxter Company Detail
Table 48. Baxter Business Overview
Table 49. Baxter Gram-Negative Bacterial Infection Therapeutics Product
Table 50. Baxter Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024) & (US$ Million)
Table 51. Baxter Recent Development
Table 52. Sanofi Company Detail
Table 53. Sanofi Business Overview
Table 54. Sanofi Gram-Negative Bacterial Infection Therapeutics Product
Table 55. Sanofi Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024) & (US$ Million)
Table 56. Sanofi Recent Development
Table 57. GlaxoSmithKline Company Detail
Table 58. GlaxoSmithKline Business Overview
Table 59. GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Product
Table 60. GlaxoSmithKline Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024) & (US$ Million)
Table 61. GlaxoSmithKline Recent Development
Table 62. Novartis Company Detail
Table 63. Novartis Business Overview
Table 64. Novartis Gram-Negative Bacterial Infection Therapeutics Product
Table 65. Novartis Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024) & (US$ Million)
Table 66. Novartis Recent Development
Table 67. Pfizer Company Detail
Table 68. Pfizer Business Overview
Table 69. Pfizer Gram-Negative Bacterial Infection Therapeutics Product
Table 70. Pfizer Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Takeda Company Detail
Table 73. Takeda Business Overview
Table 74. Takeda Gram-Negative Bacterial Infection Therapeutics Product
Table 75. Takeda Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024) & (US$ Million)
Table 76. Takeda Recent Development
Table 77. Nektar Therapeutics Company Detail
Table 78. Nektar Therapeutics Business Overview
Table 79. Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Product
Table 80. Nektar Therapeutics Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024) & (US$ Million)
Table 81. Nektar Therapeutics Recent Development
Table 82. Sumitomo Company Detail
Table 83. Sumitomo Business Overview
Table 84. Sumitomo Gram-Negative Bacterial Infection Therapeutics Product
Table 85. Sumitomo Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024) & (US$ Million)
Table 86. Sumitomo Recent Development
Table 87. Targeted Genetics Company Detail
Table 88. Targeted Genetics Business Overview
Table 89. Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Product
Table 90. Targeted Genetics Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024) & (US$ Million)
Table 91. Targeted Genetics Recent Development
Table 92. Research Programs/Design for This Report
Table 93. Key Data Information from Secondary Sources
Table 94. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gram-Negative Bacterial Infection Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Enteral Treatment Features
Figure 4. Parenteral Treatment Features
Figure 5. Topical Treatment Features
Figure 6. Global Gram-Negative Bacterial Infection Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Application: 2023 VS 2030
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Others Case Studies
Figure 11. Gram-Negative Bacterial Infection Therapeutics Report Years Considered
Figure 12. Global Gram-Negative Bacterial Infection Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Gram-Negative Bacterial Infection Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Region: 2023 VS 2030
Figure 15. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Players in 2023
Figure 16. Global Top Gram-Negative Bacterial Infection Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gram-Negative Bacterial Infection Therapeutics as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Gram-Negative Bacterial Infection Therapeutics Revenue in 2023
Figure 18. North America Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Gram-Negative Bacterial Infection Therapeutics Market Share by Country (2019-2030)
Figure 20. United States Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Gram-Negative Bacterial Infection Therapeutics Market Share by Country (2019-2030)
Figure 24. Germany Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Share by Region (2019-2030)
Figure 32. China Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Gram-Negative Bacterial Infection Therapeutics Market Share by Country (2019-2030)
Figure 40. Mexico Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Share by Country (2019-2030)
Figure 44. Turkey Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Baxter Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
Figure 47. Sanofi Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
Figure 48. GlaxoSmithKline Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
Figure 49. Novartis Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
Figure 50. Pfizer Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
Figure 51. Takeda Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
Figure 52. Nektar Therapeutics Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
Figure 53. Sumitomo Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
Figure 54. Targeted Genetics Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2019-2024)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
